EU court should help companies recoup investment on paediatric trials with maximum patent extension possible, says lawyer
This article was originally published in Scrip
Executive Summary
The Court of Justice of the European Union should go beyond the recent advocate general's opinion on negative term supplementary protection certificates (SPCs) and help pharmaceutical companies recoup part of their investments on paediatric trials, says Maria Isabel Manley, head of regulatory practice at the UK law firm, Bristows.